Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Diagnostics Chief Predicts Multiple Warning Letters For ASR Violations

This article was originally published in The Gray Sheet

Executive Summary

FDA expects to send out multiple warning letters to firms for illegally selling diagnostic products as 510(k)-exempt analyte specific reagents instead of as test kits, which are more heavily regulated
Advertisement

Related Content

FDA Says Final CLIA Waiver Guidance Eases Burdens; Industry Isn’t Satisfied
Test Makers Have One Year To Comply With New ASR Guidelines
Test Makers Have One Year To Comply With New ASR Guidelines

Topics

Advertisement
UsernamePublicRestriction

Register

MT027367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel